allogeneic anti-CD19 CAR-gamma/delta T cells QH103

A preparation of a subset of allogeneic T lymphocytes that express only gamma chain and delta chain T-cell receptors (TCRs) and that are engineered to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, with potential immunomodulating and antineoplastic activities. Upon administration, allogeneic anti-CD19 CAR-gamma/delta T cells QH103 target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. Gamma/delta T lymphocytes play a key role in the activation of the immune system and do not require major histocompatibility complex (MHC)-mediated antigen presentation to exert their cytotoxic effect. CD19 is overexpressed on certain tumor cell types.